Integrin and Cell-Adhesion Peptides
3 compounds in this family, each with its recorded mechanism, routes of administration, safety notes and references to published literature.
- ATN-161ATN‑161 (Ac‑PHSCN‑NH2) is a five‑amino‑acid peptide that antagonises integrin α5β1 (β1‑integrin) signaling. It is being investigated intravenously as an anti‑angiogenic agent in cancer, a potential inhibitor of SARS‑CoV‑2 spike‑protein binding, and a modulator of inflammatory pathways in pancreatitis and Parkinson’s disease. The compound remains investigational, with safety data from a phase‑1 oncology trial and pre‑clinical efficacy reported in animal models and in‑vitro studies.
- EptifibatideEptifibatide is a cyclic heptapeptide that acts as a Glycoprotein IIb/IIIa (integrin αIIbβ3) inhibitor. It is approved for intravenous use and is marketed for cardiovascular indications where rapid platelet inhibition is required. The drug blocks the final common pathway of platelet aggregation, thereby reducing thrombus formation.
- Technetium Tc-99m maraciclatideTechnetium-99m maraciclatide (also called 99mTc‑maraciclatide or NC100692) is an investigational radiopharmaceutical that binds the αvβ3 integrin. It is used experimentally for gamma‑camera imaging to visualise integrin expression in inflamed joints of rheumatoid arthritis and in bone metastases of prostate cancer, providing a whole‑body snapshot of disease activity.